Skip to main content
SpringerLink
Log in

Epidemiology of Progessive Supranuclear Palsy and Multiple System Atrophy

  • Chapter
Atypical Parkinsonian Disorders

Part of the book series: Current Clinical Neurology ((CCNEU))

  • 1102 Accesses

Abstract

Epidemiology seeks to prevent disease by identifying risk factors, be they genetic and/or environmental, that are of etiological relevance through the use of descriptive studies, natural experiments, and very occasionally randomized trials. In addition, clinical epidemiology can examine the utility of diagnostic tests, determine predictors of disease prognosis, and test whether therapies can modify disease progression. This chapter will focus on descriptive studies that have either measured disease frequency (prevalence or incidence) or estimated the risk associated with environmental exposures. We have chosen to focus solely on progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) as there is hardly any data for other atypical parkinsonian disorders such as corticobasal degeneration or dementia with Lewy bodies. For any uncommon disease, undertaking epidemiological studies presents several major challenges: case identification, representativeness of cases, and obtaining adequate sample sizes. For both PSP and MSA, there are additional problems as both these conditions can be difficult to diagnose. As there are no adequate tests that are both highly sensitive and specific, the gold standard remains the diagnostic expertise of a movement disorders specialist (1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 299.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 379.00
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125:861–870

    Article  PubMed  Google Scholar 

  2. Gilman S, Low P, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999;163(1):94–98.

    Article  PubMed  CAS  Google Scholar 

  3. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47(1):1–9.

    PubMed  CAS  Google Scholar 

  4. Litvan I, Bhatia KV, Burn DJ, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 2003;18(5): 467–486.

    Article  PubMed  Google Scholar 

  5. Rajput AH, Offord KP, Beard M, Kurland LT. Epidemiology of parkinsonism: incidence, classification and mortality. Ann Neurol 1984;16:278–282.

    Article  PubMed  CAS  Google Scholar 

  6. Golbe LI, Davis PH, Schoenberg, et al. Prevalence and Natural History of Progressive Supranuclear Palsy. Neurology 1988;38:1031–1034.

    PubMed  CAS  Google Scholar 

  7. Radhakrishnan K, Thacker AK, Maloo JC, et al Descriptive epidemiology of some rare neurological diseases in Benghazi, Libya. Neuroepidemiology 1988;7(3):159–164.

    Article  PubMed  CAS  Google Scholar 

  8. Morgante L, Rocca WA, Di Rosa AE, et al. Prevalence of Parkinson’s disease and other types of Parkinsonism: a door-to-door survey in three Sicillian municipalities. Neurology 1992;42:1901–1907.

    PubMed  CAS  Google Scholar 

  9. de Rijk MC, Breteler MMB, Graveland GA, et al. Prevalence of Parkinson’s disease in the elderly: the Rotterdam Study. Neurology, 1995;45(12):2143–2146.

    PubMed  Google Scholar 

  10. Trenkwalder C, Schwarz J, Gebhard J, et al. Starnberg trial on epidemiology of Parkinsonism and hypertension in the elderly. Prevalence of Parkinson’s disease and related disorders assessed by a door-to-door survey of inhabitants older than 65 years. Arch Neurol 1995;52(10):1017–1022.

    PubMed  CAS  Google Scholar 

  11. Bower JH, Maranganore DM, McDonnell SK, Rocca W. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 1997;49(5):1284–1288.

    PubMed  CAS  Google Scholar 

  12. Wermuth, L, Joensen P, Bunger N, Jeune B. High prevalence of Parkinson’s disease in the Faroe Islands. Neurology 1997;49(2):426–432.

    PubMed  CAS  Google Scholar 

  13. Chio A, Magnani C, Schiffer D. Prevalence of Parkinson’s disease in Northwestern Italy: comparison of tracer methodology and clinical ascertainment of cases. Mov Disord 1998;13(3):400–405.

    Article  PubMed  CAS  Google Scholar 

  14. Schrag A., Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 1999;354:1771–1775.

    Article  PubMed  CAS  Google Scholar 

  15. Nath U, Ben-Shlomo Y, Thomson RG, et al. The Prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. Brain 2001;124:1438–1449.

    Article  PubMed  CAS  Google Scholar 

  16. Matthews WB, Compston A, Allen IV, Martyn CN. McAlpine’s Mmultiple sclerosis, 2 ed. Edinburgh: Churchill Livingstone, 1990.

    Google Scholar 

  17. de Rijk MC, Tzourio C, Breteler MM, et al. Prevalence of parkinsonism and Parkinson’s disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson’s disease. J Neurol Neurosurg Psychiatry 1997;62:10–15.

    Article  PubMed  Google Scholar 

  18. Steele JC, Caparros-Lefebvre D, Lees AJ, Sacks OW. Progressive supranuclear palsy and its relation to pacific foci of the parkinsonism-dementia complex and Guadeloupean parkinsonism. Parkinsonism Relat Disord 2003;9: 39–54.

    Article  Google Scholar 

  19. Chaudhuri KR, Hu MT, Brooks DJ. Atypical parkinsonism in Afro-Caribbean and Indian origin immigrants to the UK. Mov Disord 2000;15(1):18–23.

    Article  PubMed  CAS  Google Scholar 

  20. Duvoisin RC, Yahr MD, Schweitzer MD, Merritt HH. Parkinsonism before and since the epidemic of Encephalitis Lethargic. Arch Neurol 1963;9:232–236.

    PubMed  CAS  Google Scholar 

  21. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:970–980.

    Article  Google Scholar 

  22. Sanchez-Ramos JR, Hefti F, Weiner WJ. Paraquat and Parkinson’s disease. Neurology 1987;37: 728.

    PubMed  CAS  Google Scholar 

  23. Caparros-Lefebvre D, Elbaz A, and the Caribbean Parkinsonism Study Group. Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study. Lancet 1999; 354:281–286.

    Article  PubMed  CAS  Google Scholar 

  24. Davis PH, Golbe LI, Duvoisin RC, Schoenberg BS. Risk factors for progressive supranuclear palsy. Neurology 1988;38(10):1546–1552.

    PubMed  CAS  Google Scholar 

  25. Golbe LI, Rubin RS, Cody RP et al. Follow-up study of risk factors in progressive supranuclear palsy. Neurology 1996;47(1):148–54.

    PubMed  CAS  Google Scholar 

  26. Nee LE, Gomez MR, Dambrosia J, Bale S, Eldridge R, Polinsky RJ. Environmental-occupational risk factors and familial associations in multiple system atrophy: a preliminary investigation. Clin Auton Res 1991;1(1): 9–13.

    Article  PubMed  CAS  Google Scholar 

  27. Vanacore, N., et al., Smoking habits in multiple system atrophy and progressive supranuclear palsy. European Study Group on Atypical Parkinsonisms. Neurology 2000;54(1):114–119.

    PubMed  CAS  Google Scholar 

  28. Hanna PA, Jankovic J, Kirkpatrick JB. Multiple system atrophy: the putative causative role of environmental toxins. Arch Neurol 1999;56(1):90–94.

    Article  PubMed  CAS  Google Scholar 

  29. McCrank E. PSP risk factors. Neurology 1990; 40:1637.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Regional Neurosciences Centre, University of Newcastle-upon-Tyne, Newcastle-upon-Tyne, UK

    Adam Zermansky MBCHB, MRCP

  2. Department of Social Medicine, University of Bristol, Bristol, UK

    Yoav Ben-Shlomo MRCP, FFPHM

Authors
  1. Adam Zermansky MBCHB, MRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoav Ben-Shlomo MRCP, FFPHM
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Movement Disorder Program, Department of Neurology, University of Louisville School of Medicine, Louisville, KY

    Irene Litvan MD (Raymond Lee Lebby Professor of Parkinson Disease Research, Director) (Raymond Lee Lebby Professor of Parkinson Disease Research, Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Zermansky, A., Ben-Shlomo, Y. (2005). Epidemiology of Progessive Supranuclear Palsy and Multiple System Atrophy. In: Litvan, I. (eds) Atypical Parkinsonian Disorders. Current Clinical Neurology. Humana Press. https://doi.org/10.1385/1-59259-834-X:023

Download citation

  • DOI: https://doi.org/10.1385/1-59259-834-X:023

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-331-2

  • Online ISBN: 978-1-59259-834-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation